Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Pfizer
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
Pfizer announces FDA approval of Abrysvo
Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine,
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
ETF Daily News
12h
Copeland Capital Management LLC Makes New $144,000 Investment in Pfizer Inc. (NYSE:PFE)
Abrysvo
, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. Receive ...
15h
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
6d
Why I'm Considering Leaning Heavily Into Pfizer
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
23h
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
1d
Pregnant women in Singapore can get jab to protect babies from respiratory infection from Nov 1
Antibodies from the Abrysvo vaccine will be passed from the mothers to the babies. Read more at straitstimes.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback